Humacyte Inc (NASDAQ: HUMA) established initial surge of 0.65% at $1.55, as the Stock market unbolted on Wednesday, before settling in for the price of $1.54 at the close. Taking a more long-term approach, HUMA posted a 52-week range of $1.15-$9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was 42.43%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 39.28%. This publicly-traded company’s shares outstanding now amounts to $130.03 million, simultaneously with a float of $125.74 million. The organization now has a market capitalization sitting at $240.43 million. At the time of writing, stock’s 50-day Moving Average stood at $2.8274, while the 200-day Moving Average is $4.9059.
Humacyte Inc (HUMA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Humacyte Inc industry. Humacyte Inc’s current insider ownership accounts for 18.94%, in contrast to 27.76% institutional ownership. According to the most recent insider trade that took place on Apr 14 ’25, this organization’s Chief Commercial Officer bought 6,493 shares at the rate of 1.54, making the entire transaction reach 9,999 in total value, affecting insider ownership by 22,018. Preceding that transaction, on Apr 10 ’25, Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for 1.53, making the whole transaction’s value amount to 30,600. This particular insider is now the holder of 40,600 in total.
Humacyte Inc (HUMA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
Humacyte Inc’s EPS increase for this current 12-month fiscal period is 39.28% and is forecasted to reach -0.33 in the upcoming year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Let’s observe the current performance indicators for Humacyte Inc (HUMA). It’s Quick Ratio in the last reported quarter now stands at 2.40. The Stock has managed to achieve an average true range (ATR) of 0.24.
In the same vein, HUMA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.26, a figure that is expected to reach -0.20 in the next quarter, and analysts are predicting that it will be -0.33 at the market close of one year from today.
Technical Analysis of Humacyte Inc (HUMA)
Now, what If we examine the latest scores posted by [Humacyte Inc, HUMA]. During the last 5-days, its volume was lower the volume of 3.43 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 80.14% While, its Average True Range was 0.2124.
Raw Stochastic average of Humacyte Inc (HUMA) in the period of the previous 100 days is set at 7.12%, which indicates a major fall in contrast to 40.82% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 156.45% that was higher than 120.84% volatility it exhibited in the past 100-days period.
